Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.COV2.S Phase 1 Study in Japanese Adults
NCT04509947Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2020
- Primary completion
- Feb 2021
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Ad26.COV2.S in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Solicited Local Adverse Events for 7 days after First Vaccination at Day 8, Number of Participants with Solicited Local Adverse Events for 7 days after Second Vaccination at Day 64 and 4 more. Started Aug 2020; status: completed.
02
Drugs
Ad26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04509947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04509947.